glp-1 users Circana highlights role of personalization in supporting weight-loss Analysis & Commentary | National
Description
With the successive launch of Glucagon-like peptide-1 (GLP-1) class drugs that allow weight loss with a once-daily pill instead of an injection, the barrier to obesity treatment is lowering
What happens when you stop taking semaglutide or tirzepatide
Research shows many people regain weight after stopping...
In its mildest form, inflammation in the gut may induce only brief discomfort or food intolerance, whereas in the extreme, gut inflammation can manifest as Crohns disease or ulcerative colitis, with life threatening implications
